The further positive data from the DREAMM-1 study, which is based on results of the pre-specified interim analysis, showed the durability and depth of response of GSK2857916 anti-BCMA
The post GSK’s anti-BCMA antibody-drug conjugate improves ORR in cancer study appeared first on Pharmaceutical Business review.
Original Article: GSK’s anti-BCMA antibody-drug conjugate improves ORR in cancer study